About two-thirds of colon resection procedures are performed via open surgery with an eight- to 12-inch incision and several weeks of recovery time. A miniature robotically assisted surgical device (RASD) developed by a company called Virtual Incision could change that.
Virtual Incision is just about ready to go to FDA seeking a 510(k) clearance for its two-pound RASD that operates entirely inside the body through a single abdominal incision and is expected to be less expensive and more portable than existing laparoscopic surgery robots. To help it get there, investors recently poured $18 million into the company.
New investor Sinopharm Capital and existing investor Bluestem Capital co-led the series B round, with participation from PrairieGold Venture Partners and others.